UBT-251 is an injectable peptide developed by United Bio-Technology in Hengqin and licensed to Novo Nordisk, described as a triple agonist at the GLP-1, GIP and glucagon receptors. ⚠️ It has no peer-reviewed literature of any kind. Eleven trials are registered, including three phase 3 studies, and not one journal publication exists; there is no published sequence, no structure, no receptor potency and no reported trial result. That combination is the most important thing to know about it.
- No safety data has been published in any form
- UBT-251 has zero PubMed-indexed literature. A direct query for 'UBT251 OR UBT-251' returns no records at all; every fact about it currently derives from company disclosures and trial registries, not peer-reviewed publication.
- It is a long-acting synthetic peptide triple agonist at the GLP-1, GIP and glucagon receptors, originated by United Biotechnology, a subsidiary of The United Laboratories International Holdings Limited (Hong Kong listed, China).
- In March 2025 Novo Nordisk took an exclusive worldwide licence excluding mainland China, Hong Kong, Macau and Taiwan, paying $200 million upfront with up to $1.8 billion in milestones plus tiered royalties; United Biotechnology retained Greater China rights.
- In February 2026 Novo Nordisk released Chinese phase 2 results: a mean HbA1c reduction of up to 2.16% after 24 weeks in Chinese patients with type 2 diabetes, and up to 19.7% mean weight loss after 24 weeks in the obesity cohort.
- As of August 2026 UBT-251 is not approved anywhere; it sits in phase 2 (China, retained by the originator) with Novo Nordisk holding development rights elsewhere. It is a direct competitor to retatrutide in the triple-agonist class.
Mechanism
No mechanism can be described from published evidence, and saying so precisely is more useful than paraphrasing a press release.
The triple- label, -1 plus GIP plus glucagon, appears in company communications and industry coverage. It could not be confirmed from any peer-reviewed source or from any sponsor-written trial description. The only registry-level support is indirect: both the originator's and Novo Nordisk's trials exclude participants who have recently taken GLP-1, GIP or glucagon receptor agonists, which is consistent with the drug being one but is not evidence of what it does.
⚠️ No EC50, Ki or IC50 value exists for UBT-251 at any receptor in PubMed or ChEMBL. ChEMBL returns no compound record at all, so there is no stored sequence, structure or identifier to work from.
If the label is right, the class rationale is well established from other triple agonists: -1 agonism drives satiation and secretion, GIP agonism appears to improve tolerability and add metabolic benefit, and glucagon agonism raises energy expenditure while risking glycaemic control. Retatrutide is the reference compound for that combination. None of that is evidence about UBT-251 specifically.
receptor fingerprint
Glucagon-like -1 receptor (GLP1R)Agonist
Glucose-dependent insulinotropic polypeptide receptor (GIPR)Agonist
Glucagon receptor (GCGR)Agonist
Evidencehow good the literature is
The evidence base is eleven trial registrations and nothing else.
Searches of PubMed for UBT251 and UBT-251 return no results. ChEMBL has no compound record. No first-in-human phase 1 trial is registered on ClinicalTrials.gov, so the early work was presumably filed with China's own registry.
Two phase 2 trials by the originator have completed. One in type 2 diabetes compared the drug against semaglutide and placebo in 211 people and finished in November 2025; one in obesity enrolled 205 people at a single site in Changsha with a 24-week endpoint and finished the same month. Neither has posted results. Further phase 2 trials in liver disease and in obesity with chronic kidney disease are recruiting, and three phase 3 trials are registered but not yet recruiting.
Novo Nordisk appears as sponsor on four further trials, which confirms the licensing arrangement at registry level: two phase 2 studies in obesity and type 2 diabetes, and two phase 1 drug-interaction studies.
⚠️ Everything else in circulation about this compound, including its headline weight-loss number and its mechanism, is press-release material.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
No safety data has been published in any form. There are no reported adverse events, no tolerability figures and no dose-limiting toxicities in the peer-reviewed literature, and no results have been posted for either completed phase 2 trial.
This is an investigational drug that has never been approved anywhere and is not available as a medicine. Material sold under this name outside a clinical trial has no established identity, purity or dose, and there is no published human safety record against which to judge any exposure. Given that even the mechanism is unconfirmed, treating it as a known quantity is not supportable.
History
UBT-251 came out of United Bio-Technology in Hengqin, part of the United Laboratories group, and drew attention in 2025 when Novo Nordisk licensed it in a deal reported at up to two billion dollars. That transaction, rather than any published result, is why the compound is discussed at all outside China. Its development pattern is characteristic of a wave of Chinese metabolic assets moving into Western pipelines through licensing rather than through the usual sequence of published early-phase work, which is why the literature is empty while the trial registry is busy.
Subjective profileweighing the evidence above
Impossible to assess, and that is the finding rather than a failure of searching. Three phase 3 trials are registered and zero papers have been published. Companies normally publish phase 1 and phase 2 results before committing to phase 3, so the asymmetry is unusual and worth noticing. The weight-loss figure widely quoted after the Novo Nordisk deal cannot be traced to any trial registry, journal or database, so it should not be treated as a sourced number. Anyone considering this compound is relying entirely on company statements.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
Limitations of the evidence
- No peer-reviewed publication of any kind exists
- No sequence, structure or receptor potency is published anywhere
- Both completed phase 2 trials have posted no results
- The widely quoted weight-loss figure cannot be traced to any registry, journal or database
- The triple-agonist mechanism itself is unverified outside company statements
Adverse effects
- No safety data has been published in any form
Notes and cautions
- There is no published safety dataset.
- As an incretin-based triple agonist the anticipated class effects are gastrointestinal; nausea, vomiting, diarrhoea and constipation, typically dose- and titration-dependent; plus the GLP-1 class concerns of pancreatitis, gallbladder disease and, in rodents, thyroid C-cell tumours, which drives the class boxed warning on approved GLP-1 receptor agonists for medullary thyroid carcinoma and MEN2.
- The glucagon receptor arm additionally raises theoretical concerns about heart rate increase and hepatic glucose output.
- None of this has been established for UBT-251 specifically, and the entry must say so rather than importing another drug's label.